Vasculitis & polymyalgia rheumatica
Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab
Authors' conclusion
Risk factors for relapse in AAV vary by treatment phase.
Study context
- Population
- Patients aged ≥15 years with relapsing AAV, PR3- or MPO-ANCA positive, in remission after reinduction with rituximab and GC (median age 59 [IQR 48–68] years; disease duration 5 [2–10] years)99 relapses (46 during maintenance)
- Participants
- 170 patients
- Comparison
- Risk factors for relapse after rituximab reinduction, by phase: maintenance (rituximab or azathioprine) vs off-treatment
- Primary endpoint
- Relapse by the next visit, risk factors in the maintenance (months 4-24) and off-treatment (months 24-48) phases
- Follow-up
- Up to 48 months
Methodological detailspost hoc analysis, generalized estimating equations logistic regression
- Post hoc analysis
- Generalized estimating equations logistic regression
Primary result
As reported in the abstract
Risk factors for relapse
Maintenance phase: musculoskeletal involvement, OR
2.8
95% CI 1.1–7.2P = 0.03
Maintenance phase: higher patient global assessment, OR
1.1
95% CI 1.0–1.2P = 0.04
Off-treatment phase: presence of CD19+ B cells, OR
2.5
95% CI 1.2–5.1P = 0.01
Off-treatment phase: reappearance of antineutrophil cytoplasmic antibody (ANCA), OR
3.2
95% CI 1.3–7.7P = 0.01
Original publication
Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab. Arthritis Rheumatol. Published 16 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →